TapImmune Inc. Provides Update On Polystart™ Vaccine Platform Applicable To Cancer And Infectious Disease
SEATTLE--(BUSINESS WIRE)--TapImmune, Inc. (OTCBB:TPIV), provides an update on the status of its PolyStartTM vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus. While the current focus of the Company’s PolyStart technology is on TapImmune’s cancer program (e.g., Her2/neu and folate receptor alpha antigens), the Company none-the-less strongly reaffirms that this core technology has widespread applicability in the development of vaccines for viral disease.
The use of the Company’s PolyStart technology increases the production of proprietary antigenic peptides of the vaccine by as much as FOUR-fold, thereby increasing vaccine potency (presenting more antigen), and potentially making manufacturing and commercialization of large volume vaccines more cost effective. While additional preclinical development is in progress, we fundamentally believe that our technology will have a significant impact in the development of vaccines for both cancer and emerging viral-disease (e.g., Ebola, Enterovirus etc).
Help employers find you! Check out all the jobs and post your resume.
The use of the Company’s PolyStart technology increases the production of proprietary antigenic peptides of the vaccine by as much as FOUR-fold, thereby increasing vaccine potency (presenting more antigen), and potentially making manufacturing and commercialization of large volume vaccines more cost effective. While additional preclinical development is in progress, we fundamentally believe that our technology will have a significant impact in the development of vaccines for both cancer and emerging viral-disease (e.g., Ebola, Enterovirus etc).
Help employers find you! Check out all the jobs and post your resume.